-
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Recruiting
More
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of
CC-94676 in men with progressive metastatic castration resistant prostate cancer.
Stanford Investigators
View full details
-
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
Recruiting
More
This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in
subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy,
one of which was an Immune Checkpoint Inhibitor (ICI).
Stanford Investigators
View full details
-
Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Not Recruiting
More
This trial will look at the safety and preliminary efficacy of SRF617 in combination with
etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate
cancer (mCRPC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Recruiting
More
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety,
tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers
of XL092 administered alone, in combination with atezolizumab, and in combination with
avelumab to subjects with advanced solid tumors.
Stanford Investigators
View full details
-
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab for Adult Participants With Advanced Prostate Cancer
Recruiting
More
The primary objective of the study is:
Dose Escalation:
• To assess the safety, tolerability, and pharmacokinetics (PK) and to determine recommended
phase 2 dosing regimen (RP2DR) of REGN4336 separately as monotherapy or in combination with
cemiplimab
Dose Expansion:
• To assess preliminary anti-tumor activity of REGN4336 as monotherapy or in combination with
cemiplimab as measured by objective response rate (ORR) per modified Prostate Cancer Working
Group (PCWG3) criteria
The secondary objectives of the study are:
Dose Escalation:
• To assess preliminary anti-tumor activity of REGN4336 as monotherapy or in combination with
cemiplimab as measured by ORR per modified PCWG3 criteria
Dose Expansion:
- To characterize the safety profile in each expansion cohort
- To characterize the PK of REGN4336 as monotherapy or in combination with cemiplimab
In both Dose Escalation and Dose Expansion:
- To assess preliminary anti-tumor activity of REGN4336 as monotherapy or in combination
with cemiplimab as measured by prostate specific antigen (PSA) decline
- To evaluate immunogenicity of REGN4336 in Module 1 and immunogenicity of REGN4336 and
cemiplimab in Module 2
Stanford Investigators
View full details
-
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Recruiting
More
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to
evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab
versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant
prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for
their prostate cancer disease.
Stanford Investigators
View full details
-
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Not Recruiting
More
The aim of this study is to provide darolutamide treatment to patients who participated in a
previous study with darolutamide supported by Bayer and the treating doctor considers that
the continuation of the treatment with darolutamide to be beneficial. Patients will be
carried over from the previous studies and continue in this study with darolutamide treatment
on the same dosage. They will also return to the study centers for doctor's visits as often
as they did in the previous study.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
Recruiting
More
This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in
participants with advanced (metastatic and/or unresectable) solid tumors.
Stanford Investigators
View full details
-
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
Recruiting
More
The purpose of this study is to assess the antitumor efficacy and safety of perioperative
enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node
dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy
[gemcitabine plus cisplatin] and RC + PLND) for participants with MIBC who are
cisplatin-eligible. The primary hypothesis is perioperative EV and pembrolizumab and RC +
PLND (Arm A) will achieve superior event free survival (EFS) compared with neoadjuvant
gemcitabine + cisplatin and RC + PLND (Arm B).
Stanford Investigators
View full details
-
177Lu-PSMA-617 Managed Access Program for mCRPC Patients
Not Recruiting
More
The purpose of this Cohort Treatment Plan is to allow access to 177Lu-PSMA-617 for eligible
patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC). The
patient's treating physician should follow the suggested treatment guidelines and comply with
all local health authority regulations.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
Not Recruiting
More
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the
efficacy and safety of atezolizumab given in combination with cabozantinib versus
cabozantinib alone in participants with inoperable, locally advanced, or metastatic renal
cell carcinoma (RCC) who experienced radiographic tumor progression during or after Immune
Checkpoint Inhibitor (ICI) treatment in the metastatic setting.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
Not Recruiting
More
This phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney)
with nivolumab to the usual approach of nephrectomy followed by standard post-operative
follow-up and monitoring, in treating patients with kidney cancer that is limited to a
certain part of the body (localized). Nivolumab is a drug that may help stimulate the immune
system to attack any cancer cells that may remain after surgery. The addition of nivolumab to
the usual surgery could prevent the cancer from returning. It is not yet known whether
nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with
kidney cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Site Public Contact, 650-498-7061.
Stanford Investigators
View full details
-
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
Not Recruiting
More
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs.
enzalutamide after confirmation of the starting dose of talazoparib in combination with
enzalutamide.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
Not Recruiting
More
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with
Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment
in Patients with Muscle-Invasive Bladder Cancer
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
Recruiting
More
The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482)
plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the
adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy.
The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo
plus pembrolizumab with respect to disease-free survival (DFS).
Stanford Investigators
View full details
-
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Not Recruiting
More
This phase II trial studies the side effects of durvalumab and chemotherapy before surgery in
treating patients with variant histology bladder cancer. Immunotherapy with monoclonal
antibodies, such as durvalumab, may induce changes in the body's immune system and may
interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,
such as methotrexate, vinblastine, doxorubicin, cisplatin, gemcitabine, and carboplatin, work
in different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving durvalumab in addition to
standard chemotherapy may lead to better outcomes in patients with variant histology bladder
cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sandy Srinivas, 650-725-2078.
Lead Sponsor
Stanford Investigators
View full details
-
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Not Recruiting
More
The primary objective of this study was to compare the two alternate primary endpoints of
radiographic progression-free survival (rPFS) and overall survival (OS) in patients with
progressive prostate-specific membrane antigen (PSMA)-positive metastatic
castration-resistant prostate cancer (mCRPC) who received 177Lu-PSMA-617 in addition to best
supportive/best standard of care (BSC/BSoC) versus patients treated with best supportive/best
standard of care alone.
Stanford is currently not accepting patients for this trial.
For more information, please contact Shermeen Poushnejad, 650-724-7662.
Stanford Investigators
View full details
-
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Not Recruiting
More
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary
efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in
subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including
bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant
prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer
(TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric
cancer/gastroesophageal junction cancer/lower esophageal cancer (GC/GEJC/LEC), colorectal
cancer (CRC), head and neck (H&N) cancer, and differentiated thyroid cancer (DTC). The study
consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib
dose for the combination with standard dosing regimen of atezolizumab will be established; in
the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the
safety and efficacy of the combination treatment in these tumor indications. Three
exploratory single-agent cabozantinib (SAC) cohorts may also be enrolled with UC, NSCLC, or
CRPC subjects. One exploratory single-agent atezolizumab (SAA) cohort may also be enrolled
with CRPC subjects. Subjects enrolled in the SAC cohorts and SAA cohort may receive
combination treatment with both cabozantinib and atezolizumab after they experience
radiographic progressive disease per the Investigator per RECIST 1.1. Due to the nature of
this study design, some tumor cohorts may complete enrollment earlier than others.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
Recruiting
More
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis,
and Coronavirus Disease 2019 with [18F]FP-R01-MG-F2 with PET/CT
Lead Sponsor
Stanford Investigators
View full details
-
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Not Recruiting
More
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth or by blocking blood flow to the tumor. Drugs used in
chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth or
tumor cells, either by killing the cells or by stopping them from dividing. It is not yet
known whether giving sunitinib malate and gemcitabine hydrochloride together is more
effective than sunitinib malate alone in treating patients with kidney cancer.
PURPOSE: This randomized phase II clinical trial is studying giving sunitinib malate together
with or without gemcitabine hydrochloride to see how well they work in treating patients with
advanced kidney cancer that cannot be removed by surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Preeti Chavan, 650-723-5957.
Stanford Investigators
View full details
-
CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
Not Recruiting
More
The primary objective of this study is to compare the progression-free survival (PFS) of
participants treated with telaglenastat and everolimus versus placebo and everolimus for
advanced or metastatic clear cell renal cell carcinoma (ccRCC) previously treated with the
following:
- At least 2 lines of therapy, including at least 1 vascular endothelial growth factor
tyrosine kinase inhibitor (VEGF TKI)
- Radiographic progression of metastatic RCC must have occurred (per investigator
assessment) on or after the most recent systemic therapy and within 6 months prior to
cycle 1 day 1
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650-736-1252.
Stanford Investigators
View full details
-
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Not Recruiting
More
This study will test an experimental drug (enfortumab vedotin) alone and with different
combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI)
that is used to treat patients with cancer of the urinary system (urothelial cancer). This
type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of
the study will look at locally advanced or metastatic urothelial cancer (la/mUC), which means
the cancer has spread to nearby tissues or to other areas of the body. Other parts of the
study will look at muscle-invasive bladder cancer (MIBC), which is cancer at an earlier stage
that has spread into the muscle wall of the bladder. This study will look at the side effects
of enfortumab vedotin alone and with other anticancer therapies. A side effect is a response
to a drug that is not part of the treatment effect. This study will also test if the cancer
shrinks with the different treatment combinations.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Not Recruiting
More
The purpose of this study is to determine how patients with metastatic castration-resistant
prostate cancer, and evidence of a homologous recombination gene deficiency, respond to
treatment with rucaparib.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Not Recruiting
More
This is a study to determine the clinical benefit (how well the drug works), safety, and
tolerability of combining varlilumab and nivolumab (also known as Opdivo® , BMS-936558). Both
drugs target the immune system and may act to promote anti-cancer effects.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
Not Recruiting
More
The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide
(ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in
patients with metastatic hormone sensitive prostate cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Not Recruiting
More
The purpose of this study is to determine whether PROSTVAC alone or in combination with
GM-CSF is effective in prolonging overall survival in men with few or no symptoms from
metastatic, castrate-resistant prostate cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650-736-1252.
Stanford Investigators
View full details
-
A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
Not Recruiting
More
This clinical study is being conducted at multiple sites to determine the best confirmed
response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell
carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic
forms; subjects with either classification will be accepted into this study.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Not Recruiting
More
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of
ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus
abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant
prostate cancer (mCRPC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Not Recruiting
More
This Phase III, open-label, randomized, multicenter study is to evaluate the efficacy and
safety of adjuvant treatment with atezolizumab compared with observation in participants with
muscle-invasive UC who are at high risk for recurrence following resection. Eligible
participants were randomized by a 1:1 ratio into atezolizumab group or control group.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650-736-1252.
Stanford Investigators
View full details
-
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Not Recruiting
More
The primary purpose of the study is to demonstrate that lenvatinib in combination with
everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C)
in improving progression-free survival (PFS) (by independent imaging review [IIR] using
Response Evaluation Criteria in Solid Tumors [RECIST 1.1]) as first-line treatment in
participants with advanced renal cell carcinoma (RCC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Not Recruiting
More
The purpose of this study is to compare the objective response rate, progression free
survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib
monotherapy in patients with previously untreated Renal Cell Cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650-736-1252.
Stanford Investigators
View full details
-
Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy
Not Recruiting
More
The purpose is to see how quickly two different types of prostate cancer participants respond
when taking enzastaurin.
Cohort 1 - asymptomatic participants with androgen-independent prostate-specific antigen
(PSA)-progressive disease without clinical or radiographic evidence of metastatic disease.
Cohort 2 - participants with androgen-independent metastatic prostate cancer (documented bone
or soft tissue metastases) with rising PSA, clinical, radiographic disease progression
following one prior docetaxel-based regimen
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Not Recruiting
More
The purpose of this study is to determine the benefit of enzalutamide versus placebo as
assessed by overall survival and progression-free survival in patients with progressive
metastatic prostate cancer who have failed androgen deprivation therapy but not yet received
chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sarah Barbeau, 6507236286.
Stanford Investigators
View full details
-
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Not Recruiting
More
This treatment protocol allows doctors to treat advanced kidney cancer with an
investigational drug called sorafenib, BAY43-9006, which is being studied in clinical trials
for kidney cancer and other kinds of cancer. This treatment protocol is not a clinical trial
in which sorafenib is compared to another equal treatment. All patients in this protocol will
be treated with sorafenib. In addition, data from the patients who participate in this
protocol will provide additional information about the drug.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
Not Recruiting
More
The purpose of this study is to collect additional safety information on abiraterone acetate
administered with prednisone to patients with metastatic castration-resistant prostate cancer
(CRPC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
Not Recruiting
More
The primary objectives of this study are the following:
Phase 1b: To identify a safe dose level of AMG 102, up to 15 mg/kg Q3W, to combine with
mitoxantrone and prednisone (MP) Phase 2: To estimate with adequate precision the effect of
the addition of AMG 102 to MP, compared with placebo plus MP, as assessed by the hazard ratio
(HR) for overall survival (OS) of previously treated subjects with castrate-resistant
prostate cancer (CRPC)
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Not Recruiting
More
This study will compare the effects, good and/or bad, of chemotherapy (Gemcitabine and
Cisplatin) with or without the addition of the chemotherapy drug Cetuximab to find out which
treatment is better.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance
Not Recruiting
More
After the diagnosis of prostate cancer, many men alter their lifestyle or diet or use various
supplements in an attempt to retard the growth of their cancer. While there is limited data
on the use of diet and supplements to alter the risk of prostate cancer, even less is known
regarding the ability of diet or supplements to alter progression. For men who have elected
active surveillance, the investigators propose to investigate the ability of vitamin D to
retard the growth of prostate cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office CCTO, 6504987061.
Lead Sponsor
Stanford Investigators
View full details
-
Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer
Not Recruiting
More
This pilot phase I trial studies the side effects and best way to give stereotactic body
radiation therapy and T-cell infusion in treating patients with metastatic kidney cancer.
Giving total body irradiation before a T-cell infusion stops the growth of cancer cells by
stopping them from dividing or killing them. After treatment, stem cells are collected from
the patient's blood and stored. Chemotherapy is given to prepare the bone marrow for the stem
cell transplant. The stem cells are then returned to the patient to replace the blood-forming
cells that were destroyed by the radiation therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650-736-1252.
Lead Sponsor
Stanford Investigators
View full details
-
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
Not Recruiting
More
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a
novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor
cell division leading to tumor growth), can reduce tumor sizes in patients with bladder
cancer
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
Not Recruiting
More
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475)
in the adjuvant treatment of adult participants who have undergone nephrectomy and have
intermediate-high risk, high risk, or M1 no evidence of disease (M1 NED) renal cell carcinoma
(RCC) with clear cell component.
The primary study hypothesis is that pembrolizumab is superior to placebo with respect to
Disease-free Survival (DFS) as assessed by the Investigator in male and female participants
with intermediate-high risk, high risk and M1 NED RCC.
Stanford is currently not accepting patients for this trial.
For more information, please contact Study Coordinator, 650-736-1252.
Stanford Investigators
View full details
-
Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
Not Recruiting
More
Primary objective was to demonstrate overall survival improvement with aflibercept compared
to placebo in patients receiving docetaxel / prednisone for metastatic androgen-independent
prostate cancer (MAIPC).
The secondary objectives were:
- To assess the efficacy of aflibercept compared to placebo on other parameters such
prostate-specific antigen (PSA) level, cancer related pain, progression free survival
(PFS), tumor-based and skeletal events and health-related quality of life (HRQL);
- To assess the overall safety in both treatment arms;
- To determine the pharmacokinetics of intravenous (IV) aflibercept in this population;
- to determine immunogenicity of IV aflibercept.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation
Not Recruiting
More
The purpose of this study is to evaluate time to progression (TTP) by PSA in patients with
high risk prostate cancer after definitive therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
View full details
-
Fulvestrant in Hormone Refractory Prostate Cancer
Not Recruiting
More
The purpose of this study is to determine if treatment with fulvestrant leads to a slowing of
tumor progression in patients who have developed androgen-independent (AIPC) or
hormone-refractory prostate cancer (HRPC) and who have a rising serum prostate specific
antigen (PSA).
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
View full details
-
Probiotic Supplementation in Preventing Treatment-Related Diarrhea in Patients With Cancer Undergoing Chemotherapy
Not Recruiting
More
This randomized phase II clinical trial studies probiotic supplementation in preventing
treatment-related diarrhea in patients with cancer undergoing chemotherapy. Probiotics may
help prevent diarrhea caused by treatment with chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650-736-1252.
Lead Sponsor
Stanford Investigators
View full details
-
Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer
Not Recruiting
More
Selenium, in the form of inorganic Sodium Selenite, may be useful for treating existing
prostate cancer. This idea is based on data from our laboratory showing that 1) prostate
cancer cells are more sensitive to Selenium (Sodium Selenite)-induced apoptosis than normal
prostate epithelial cells, 2) Selenite induces significant growth inhibition of well
established prostate cancer tumors in mice at doses that have no detectable toxicity, and 3)
Selenite disrupts AR signaling, and that the inhibition of AR expression and activity by
Selenite occurs via a redox mechanism involving GSH, superoxide, and Sp1. Altogether, these
findings suggest that Selenium may be useful in a variety of potential indications in the
natural history of prostate cancer, including both hormone sensitive and castrate resistant
prostate cancer, as a single agent, or in combination with radiation, chemotherapy or
conventional hormone therapy. Selenite is a potential novel inhibitor of AR expression and
function in prostate cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Not Recruiting
More
Primary:
To determine the duration of use of zoledronic acid in improving Bone mineral density in
patients with prostate cancer who are on hormones intermittently.
Secondary Objectives:
To describe the safety and tolerability at this dose and schedule
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
View full details
-
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Not Recruiting
More
The purpose of the ATLAS study is to determine how patients with locally advanced
unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
Not Recruiting
More
The purpose of the study is to determine whether lenalidomide is safe and effective for use
in combination with docetaxel and prednisone for the treatment of subjects with metastatic
Castrate-Resistant Prostate Cancer.
The addition of lenalidomide to docetaxel and prednisone is proposed to increase the life
expectancy of these subjects.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
Not Recruiting
More
This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral
small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the
immune system. This trial will study the safety, tolerability, and anti-tumor activity of
ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor
against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor.
Adenosine suppresses the anti-tumor activity of T cells and other immune cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
Not Recruiting
More
This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in
participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Belle Li, .
Stanford Investigators
View full details
-
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
Not Recruiting
More
The primary objectives of this study are:
1. To explore the antitumor activity of MEDI-522 in combination with docetaxel, prednisone,
and zoledronic acid in patients with metastatic Androgen-Independent Prostate Cancer
(AIPC); and
2. To summarize the safety of MEDI-522 in combination with docetaxel, prednisone, and
zoledronic acid in this patient population.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
Not Recruiting
More
The purpose of this study is to test the safety and tolerability of tivozanib (AV-951) and
Torisel™ given in combination for renal cell cancer. The study will also assess the effects
of the combination of tivozanib (AV-951) and Torisel™ on the tumor. Tivozanib (AV-951) is a
VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking
blood flow to the tumor. Temsirolimus is an mTOR inhibitor which is approved for the
treatment of advanced renal cell carcinoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
Not Recruiting
More
This phase II trial studies how well cisplatin and gemcitabine hydrochloride with or without
berzosertib works in treating patients with urothelial cancer that has spread to other places
in the body (metastatic). Drugs used in chemotherapy, such as cisplatin and gemcitabine
hydrochloride, work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Berzosertib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It
is not yet known if cisplatin and gemcitabine hydrochloride work better alone or with
berzosertib in treating patients with urothelial cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sandy Srinivas, 650-498-7061.
Stanford Investigators
View full details
-
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Not Recruiting
More
This randomized phase III trial studies how well standard-dose combination chemotherapy works
compared to high-dose combination chemotherapy and stem cell transplant in treating patients
with germ cell tumors that have returned after a period of improvement or did not respond to
treatment. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin,
carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by
stopping them from dividing or killing them. Giving colony-stimulating factors, such as
filgrastim or pegfilgrastim, and certain chemotherapy drugs, helps stem cells move from the
bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to
prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the
patient to replace the blood-forming cells that were destroyed by the chemotherapy. It is not
yet known whether high-dose combination chemotherapy and stem cell transplant are more
effective than standard-dose combination chemotherapy in treating patients with refractory or
relapsed germ cell tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)
Not Recruiting
More
Based on both pre-clinical and clinical data, it may be advantageous to administer a cancer
vaccine before chemotherapy to enhance immune responses, thus leading to a more effective
therapeutic approach for subjects with metastatic HRPC. This clinical study will evaluate the
role of combination therapy of TroVax® plus Docetaxel vs. Docetaxel alone on the progression
free survival (PFS) of subjects with HRPC.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
Not Recruiting
More
This is a multi-center, first-in-human, open-label, Phase 1/2A dose-escalation study in which
eligible patients with metastatic castration-resistant prostate carcinoma (mCRPC) will
receive oral doses of TRC253. The study will be conducted in 2 parts: part 1 (dose
escalation) and part 2 (dose expansion).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Not Recruiting
More
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus
prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with
metastatic castration-resistant prostate cancer (CRPC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
Not Recruiting
More
To determine:
- Anti-tumor activity of IPI-504 in 2 groups of subjects with hormone resistant prostate
cancer.
- Group A - subjects who have not previously received chemotherapy
- Group B - sujects who have received prior chemotherapy or could not tolerate
chemotherapy.
- Clinical response will be determined by PSA and radiological response
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Not Recruiting
More
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men
with high-risk non-metastatic castration-resistant prostate cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650-736-1252.
Stanford Investigators
View full details
-
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Not Recruiting
More
The purpose of this study was to evaluate the progression free survival (PFS), based on
investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic
renal cell carcinoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Not Recruiting
More
The purpose of this treatment protocol is to provide expanded access to MDV3100 and monitor
its safety in patients with metastatic castration-resistant prostate cancer previously
treated with docetaxel-based chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
Not Recruiting
More
This randomized phase III trial studies sunitinib malate to see how well it works compared to
sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed
by surgery. Sunitinib malate and sorafenib tosylate may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Giving sunitinib malate or sorafenib tosylate after surgery may kill any tumor cells that
remain after surgery. It is not yet known whether sunitinib malate is more effective than
sorafenib tosylate or placebo in treating kidney cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer
Not Recruiting
More
The primary purpose of this study is to evaluate the ability of oral triamcinalone given
twice a day to patients with androgen independent prostate cancer to produce a sustained
biochemical response. Secondary goals are to describe the safety and tolerability at this
dose and schedule, to determine the time to sustained biochemical response, to determine the
duration of biochemical response, to determine the time to disease progression.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
View full details
-
Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma
Not Recruiting
More
This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in
treating patients with stage I-IIa testicular seminoma. The retroperitoneum is the space in
the body behind the intestines that is typically the first place that seminoma spreads. RPLND
is a surgery that removes lymph nodes in this area to treat testicular seminoma and may
experience fewer long-term toxicities, such as a second cancer, cardiovascular disease,
metabolic syndrome (pre-diabetes), or lung disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Not Recruiting
More
This is an open-label, multicenter, single-arm, expanded access program (EAP) designed to
provide atezolizumab access to participants with locally advanced or metastatic urothelial
carcinoma that has progressed on, or is intolerant to, a platinum-containing chemotherapy
regimen.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Not Recruiting
More
The purpose of this study is to evaluate the objective response rate (complete response [CR]+
partial response [PR]) of the selected dose regimen in participants with metastatic or
surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Not Recruiting
More
To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed
tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE
MRI) are better predictors of response to therapy than the current standard of care (CT or
MRI).
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrew Quon, 6507361369.
Lead Sponsor
Stanford Investigators
View full details
-
NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
Not Recruiting
More
This pilot clinical trial studies combined fluorine F 18 sodium fluoride (NaF)/
fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and magnetic resonance imaging
(MRI) in measuring response to a drug, radium Ra 223 dichloride (Ra-223), in treating
patients with prostate cancer that has not responded to hormone therapy and has spread to
other parts of the body. Combining NaF/FDG in a simultaneous PET/MRI scan may help doctors
accurately measure how well patients respond to treatment with radium Ra 223 dichloride.
Stanford is currently not accepting patients for this trial.
For more information, please contact Omar Rutledge, 650-721-4089.
Lead Sponsor
Stanford Investigators
View full details
-
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Not Recruiting
More
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line
MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab
Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
Not Recruiting
More
The primary focus of this study is to see if looking at tumor biomarkers using a program
called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy
before surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Preeti Chavan, 650-723-5957.
Stanford Investigators
View full details
-
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Not Recruiting
More
Open-label, multi-center, multi-national rollover study to allow continued access to
tivozanib for subjects who have participated in other tivozanib (monotherapy or combination)
protocols. Eligible subjects will continue to receive tivozanib at the same dose and schedule
as per the original (parent) protocol. The length of time that a subject must be on the
parent protocol before rolling over to this protocol will be dictated by the (original)
parent protocol. Subjects will be seen by the investigator every 4 weeks (± 5 days). Adverse
events and blood pressure will be recorded. At the beginning of Cycle 1 and at the beginning
of every odd-numbered cycle (Cycle 3, Cycle 5, etc), clinical laboratory values will be
recorded. CT scans to assess disease will be performed at the end of even-numbered cycles
(Cycle 2, Cycle 4, etc).
Stanford is currently not accepting patients for this trial.
For more information, please contact Sarah Barbeau, 6507236286.
Stanford Investigators
View full details
-
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
Not Recruiting
More
To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in
bladder cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
Lead Sponsor
Stanford Investigators
View full details
-
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
Not Recruiting
More
The purpose of Part 1 of this study is to evaluate the safety and tolerability of
dalantercept in combination with axitinib in patients with advanced renal cell carcinoma
(RCC) to determine the recommended dose level of dalantercept in combination with axitinib
for Part 2.
The purpose of Part 2 of this study is to determine whether treatment with dalantercept in
combination with axitinib prolongs progression free survival (PFS) compared to axitinib alone
in patients with advanced renal cell carcinoma (RCC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650-736-1252.
Stanford Investigators
View full details
-
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
Not Recruiting
More
Determine time-to-progression (TTP) for an escalating dose schedule for subjects with
progressive metastatic renal cell carcinoma treated with sorafenib
Stanford is currently not accepting patients for this trial.
For more information, please contact Haas Denise, 6507361252.
Lead Sponsor
Stanford Investigators
View full details
-
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
Not Recruiting
More
This Phase II, single-arm study is designed to evaluate the effect of atezolizumab treatment
in participants with locally advanced or metastatic urothelial bladder cancer. Participants
will be enrolled into 1 of 2 cohorts. Cohort 1 will consist of participants who are
treatment-naïve and ineligible for cisplatin-containing chemotherapy. The results of Cohort 1
are reported separately (NCT02951767). Cohort 2 (reported here) will contain participants who
have progressed during or following a prior platinum-based chemotherapy regimen. Participants
in both cohorts will be given a 1200 milligrams (mg) intravenous (IV) dose of atezolizumab on
Day 1 of 21-day cycles. Treatment of participants in Cohort 1 will continue until disease
progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or
unmanageable toxicity. Treatment of participants in Cohort 2 will continue until loss of
clinical benefit or unmanageable toxicity.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650-736-1252.
Stanford Investigators
View full details
-
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
Not Recruiting
More
The primary objective is to compare the diagnostic performance of 18F- Fluoride PET/CT
scanning to that of conventional bone scanning for detecting cancer that has spread to the
bone (bone metastasis). The intent of the study is to determine whether 18F-Fluoride PET/CT
will lead to improved treatment and patient outcomes.
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrei Iagaru, 6507362859.
Stanford Investigators
View full details
-
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Not Recruiting
More
Bone metastases and associated pain are a major cause of morbidity and mortality in
castration-resistant prostate cancer (CRPC). Most approved therapies have shown some ability
to reduce soft tissue lesions but none meaningfully impacts bone metastases (as demonstrated
by lack of resolution of lesions on bone scan with these agents) or the pain associated with
these metastases.
This study will evaluate the effect of cabozantinib versus mitoxantrone plus prednisone on
pain response and bone scan response in men with CRPC.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Not Recruiting
More
This randomized phase III trial studies gemcitabine hydrochloride, cisplatin, and bevacizumab
to see how well they work compared with gemcitabine hydrochloride and cisplatin in treating
patients with urinary tract cancer that has spread to other places in the body. Drugs used in
chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Immunotherapy with bevacizumab, may induce changes in body's
immune system and may interfere with the ability of tumor cells to grow and spread. It is not
yet known whether gemcitabine hydrochloride and cisplatin are more effective when given with
or without bevacizumab in treating patients with urinary tract cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Preeti Chavan, 6507250426.
Stanford Investigators
View full details
-
Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma
Not Recruiting
More
This pilot clinical trial studies perfusion computed tomography (CT) in predicting response
to treatment in patients with advanced kidney cancer. Comparing results of diagnostic
procedures done before, during, and after targeted therapy may help doctors predict a
patient's response to treatment and help plan the best treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Yoriko Imae, 650-498-5186.
Lead Sponsor
Stanford Investigators
View full details
-
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
Not Recruiting
More
The purpose of this study is to learn about the safety and effectiveness of two different
drug combinations in patients who have intermediate- and poor-risk germ cell tumors (GCT).
One combination of drugs, paclitaxel, ifosfamide and cisplatin (TIP), is experimental. The
other combination of drugs, bleomycin, etoposide and cisplatin (BEP), is the standard of care
treatment for intermediate- and poor-risk germ cell tumors. However, BEP does not cure every
patient and therefore newer treatments are needed.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650-736-1252.
Stanford Investigators
View full details
-
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
Not Recruiting
More
The purpose of this study is to test an investigational drug, vinflunine (BMS-710485), in
combination with gemcitabine in patients with Transitional Cell Carcinoma who cannot be
treated with cisplatin. This study will help to determine whether vinflunine in combination
with gemcitabine will extend the time period until further growth of the tumor more than
gemcitabine alone.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Not Recruiting
More
This study evaluates if temsirolimus causes a reduction in the serum levels of
prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer
(CRPC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
Not Recruiting
More
This randomized Phase III study is to evaluate whether pazopanib compared with placebo can
prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of
developing recurrence after undergoing kidney cancer surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650736-1252.
Stanford Investigators
View full details
-
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
Not Recruiting
More
This study evaluates if itraconazole causes a reduction in the serum levels of
prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer
(CRPC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
View full details
-
68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
Not Recruiting
More
This clinical trial studies gallium-68 (68Ga)-prostate specific membrane antigen (PSMA)
(gallium Ga 68-labeled PSMA ligand Glu-urea-Lys[Ahx]) positron emission tomography
(PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in identifying
prostate cancer that may have returned after a period of improvement (biochemical
recurrence). 68Ga-PSMA is a radiopharmaceutical that localizes to a specific prostate cancer
receptor, which can then be imaged by the PET/CT or PET/MRI scanner.
Stanford is currently not accepting patients for this trial.
For more information, please contact Pamela Gallant, 650-736-8965.
Lead Sponsor
Stanford Investigators
View full details
-
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
Not Recruiting
More
The purpose of this study is to evaluate the effect of the combination of mitoxantrone and
granulocyte-macrophage colony stimulating factor (GM-CSF) on progression-free survival (PFS)
and overall survival (OS), in patients with hormone-refractory prostate cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
View full details
-
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Not Recruiting
More
The purpose of this study is to determine the safety and efficacy of enzalutamide vs
bicalutamide in asymptomatic or mildly symptomatic patients with prostate cancer who have
disease progression despite primary androgen deprivation therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sarah Barbeau, 6507236286.
Stanford Investigators
View full details
-
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Not Recruiting
More
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote
anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias
and lymphomas), as well as patients with select types of solid tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Vargas, 650-723-0371.
Stanford Investigators
View full details
-
Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
Not Recruiting
More
The purpose of this trial is to confirm a safe dose of AS1404, to be given with docetaxel,
and to see whether adding AS1404 and docetaxel together improves the outcome of the
treatment, when compared to docetaxel alone.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
Not Recruiting
More
This is an open-label, single-arm, multicentre, global, phase II study designed to evaluate
the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma (PRCC) who
are treatment naïve or previously treated.
An independent central pathology review of tumour samples will be used to confirm the
diagnosis of PRCC of all patients enrolling. However, locally available pathology results
confirming PRCC will be allowed for timely study entry.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650-736-1252.
Stanford Investigators
View full details
-
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Not Recruiting
More
This study will evaluate the safety and efficacy of Dovitinib versus sorafenib in patients
with metastatic renal cell cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sarah Barbeau, 6507236286.
Stanford Investigators
View full details
-
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Not Recruiting
More
The purpose of the study is to compare the clinical benefit, as measured by duration of
overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic
clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650-736-1252.
Stanford Investigators
View full details
-
Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy
Not Recruiting
More
RATIONALE: Studying samples of blood in the laboratory from patients receiving radiation
therapy and chemotherapy may help doctors learn more about the effects of this treatment on
cells. It may also help doctors understand how well patients respond to treatment.
PURPOSE: This research study is studying biomarkers in blood samples from young patients with
newly diagnosed brain tumors undergoing standard radiation therapy and chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Not Recruiting
More
The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal
Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response
relationship exists.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sarah Barbeau, 6507236286.
Stanford Investigators
View full details
-
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
Not Recruiting
More
The purpose of this study is to determine the efficacy of the combination of thalidomide and
capecitabine in metastatic renal cell carcinoma and also to determine the safety of the
combination.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
View full details
-
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Not Recruiting
More
This phase II trial studies how well giving bicalutamide with or without Akt inhibitor MK2206
works in treating patients with previously treated prostate cancer. Androgens can cause the
growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the
amount of androgens made by the body. Akt inhibitor MK2206 may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. It is not yet known whether
bicalutamide is more effective with or without Akt inhibitor MK2206 in treating prostate
cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Preeti Chavan, 650-725-0426.
Stanford Investigators
View full details
-
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
Not Recruiting
More
This randomized phase II trial studies how well tivantinib with or without erlotinib
hydrochloride works in treating patients with metastatic or locally advanced kidney cancer
that cannot be removed by surgery. Tivantinib and erlotinib hydrochloride may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Preeti Chavan, 650-725-0426.
Stanford Investigators
View full details
-
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Not Recruiting
More
This study was conducted to examine survival, disease-free survival, safety, and the
magnitude of the immune response induced following administration of DN24-02 in subjects with
HER2+ urothelial carcinoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Not Recruiting
More
This study is a prospective, interventional, open-label, multi-center early access program
for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis
and to collect additional short and long term safety data on the product.
Stanford is currently not accepting patients for this trial.
For more information, please contact Elizabeth Chitouras, 650-498-0623.
Stanford Investigators
View full details
-
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
Not Recruiting
More
The purpose of this study is to evaluate the safety and pharmacokinetics of enfortumab
vedotin as well as assess the immunogenicity and antitumor activity in subjects with
metastatic urothelial cancer and other malignant solid tumors that express Nectin-4.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
Not Recruiting
More
The purpose of this trial is to determine if adjuvant therapy with axitinib will prevent or
delay the recurrence of renal cell cancer after surgery to remove the primary tumor in high
risk patients.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650-736-1252.
Stanford Investigators
View full details
-
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Not Recruiting
More
A 2-part, Phase 1-2, open-label, parallel group, randomized study in patients with
Castration-Resistant Prostate Cancer (CRPC) who are no longer responding to treatment with
abiraterone and steroids. In Part A (Phase 1), patients will continue to receive the same
doses of abiraterone and steroids they were receiving prior to study entry and will be
randomized to receive 1 of 2 different treatment regimens of AT13387 in combination with
abiraterone. Once the best regimen is established in Part A, based on safety and antitumor
activity, patients will be randomized to the selected treatment regimen and dose of AT13387
in combination with abiraterone or AT13387 alone in Part B (Phase 2).
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650-736-1252.
Stanford Investigators
View full details
-
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
Not Recruiting
More
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of
SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell
carcinoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
Not Recruiting
More
To determine whether, in this patient population, treatment with calcitriol and Naproxen is
more effective in delaying the growth of prostate cancer than treatment with calcitriol alone
as seen in historical controls.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Lead Sponsor
Stanford Investigators
View full details
-
A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)
Not Recruiting
More
This is a Phase II, multicenter, randomized, blinded, placebo-controlled study designed to
evaluate the safety and efficacy of combining bevacizumab with sunitinib relative to placebo
with sunitinib in patients with metastatic RCC who have not received prior systemic therapy
for metastatic disease. The study will enroll approximately 100 patients at approximately 20
centers in the United States.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Not Recruiting
More
The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs)
following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
Not Recruiting
More
To determine the safety and efficacy of the combination of bevacizumab and everolimus
(RAD001) for the treatment of metastatic renal cell cancer
Stanford is currently not accepting patients for this trial.
For more information, please contact Sarah Barbeau, 650-723-6286.
Stanford Investigators
View full details
-
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Not Recruiting
More
We will combine an oral investigational vascular endothelial growth factor (VEGF inhibitor)
called pazopanib which is being studied in kidney cancer will be combined with standard
chemotherapy called taxol in patients with relapsed recurrent urothelial cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 650-736-1252.
Stanford Investigators
View full details
-
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
Not Recruiting
More
This phase III trial studies how well pembrolizumab works in treating patients with bladder
cancer that has spread into the deep muscle of the bladder wall (muscle-invasive) or
urothelial cancer that has spread from where it started to nearby tissue or lymph nodes
(locally advanced). Monoclonal antibodies recognizing and blocking checkpoint molecules can
enhance the patient's immune response and therefore help fight cancer. Pembrolizumab is one
of the monoclonal antibodies that block the PD-1 axis and can interfere with the ability of
tumor cells to grow.
Stanford is currently not accepting patients for this trial.
For more information, please contact Site Public Contact, 650-498-7061.
Stanford Investigators
View full details
